On tradipitin and beyond the gastroparesis program, the Odyssey study for tradipitin based with COVID-19 pneumonia is growing, while the tradipitin motion sickness study is on hold due to pandemic-related travel restrictions.

Jul 28, 2021 / CEO / receipt, needs a key / Mahalas Polymeropoulos, CEO | earnings call 2021-07-28 | transcript 28f8b417-2d28-4272-9d7f-8b92aec7fd07 | chars 12045-12270 | segment 11